Want to see PVLA full AI Analyst Report?
PVLA Stock Chart & Stats
$130.01
-$0.34(-2.31%)
At close: 4:00 PM EST
$130.01
-$0.34(-2.31%)
Day’s Range― - ―
52-Week Range$34.57 - $161.38
Previous CloseN/A
Volume11.83K
Average Volume (3M)306.02K
Market Cap
$2.04B
Enterprise Value$1.39K
Total Cash (Recent Filing)$261.85M
Total Debt (Recent Filing)$584.00K
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Aug 13, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.17
Shares Outstanding14,342,844
10 Day Avg. Volume270,477
30 Day Avg. Volume306,019
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)42.09
Price to Sales (P/S)0.00
P/FCF Ratio-47.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$233.55Price Target Upside79.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-5.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical & Regulatory MomentumPositive Phase 3 SELVA results plus multiple expedited regulatory designations and a rolling FDA review materially de-risk Palvella's lead program over the coming months. This advances a clear NDA pathway and, if sustained, creates a durable route to first-in-disease approval and market entry.
Strong Balance Sheet & FundingA sizable, recently upsized financing provides multi-quarter runway to complete NDA filing, invest in commercialization readiness, and support additional trials. Combined with very low reported debt, this capital base meaningfully reduces near-term liquidity risk and supports execution toward regulatory milestones.
Strengthened Governance & Commercial BenchAdding an experienced rare-disease commercial executive to the board and expanding equity incentives strengthens oversight and launch capability. This improves long-term execution odds for market access, sales force build-out, and reimbursement strategy—key durable drivers for a pre-commercial biotech.
Bears Say
No Product RevenueAs a clinical-stage company with no commercialized products, Palvella has zero product revenue and mounting net losses. Sustainable profitability depends on successful regulatory approval and commercial uptake, so near-term fundamentals remain tied to binary development outcomes rather than recurring cash flow.
Accelerating Cash BurnOperating cash flow and free cash flow are increasingly negative, reflecting higher R&D and G&A as the company prepares for NDA and launch. Even with current cash reserves, accelerating burn means Palvella remains dependent on capital markets or milestones to replenish resources before sustained commercial revenues.
Pre-commercial Execution RiskTransitioning from clinical success to revenue requires building a salesforce, securing reimbursement, and achieving adoption in rare-disease clinics. These operational and market-access tasks carry execution and timing risk that could delay revenue realization beyond current timelines and pressure cash runway.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics, Inc.’s price range in the past 12 months?
Palvella Therapeutics, Inc. lowest stock price was $34.57 and its highest was $161.38 in the past 12 months.
What is Palvella Therapeutics, Inc.’s market cap?
Palvella Therapeutics, Inc.’s market cap is $2.04B.
When is Palvella Therapeutics, Inc.’s upcoming earnings report date?
Palvella Therapeutics, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 20 days.
How were Palvella Therapeutics, Inc.’s earnings last quarter?
Palvella Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.2 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Palvella Therapeutics, Inc. overvalued?
According to Wall Street analysts Palvella Therapeutics, Inc.’s price is currently Undervalued.
Does Palvella Therapeutics, Inc. pay dividends?
Palvella Therapeutics, Inc. does not currently pay dividends.
What is Palvella Therapeutics, Inc.’s EPS estimate?
Palvella Therapeutics, Inc.’s EPS estimate is -1.18.
How many shares outstanding does Palvella Therapeutics, Inc. have?
Palvella Therapeutics, Inc. has 14,342,844 shares outstanding.
What happened to Palvella Therapeutics, Inc.’s price movement after its last earnings report?
Palvella Therapeutics, Inc. reported an EPS of -$1.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.991%.
Which hedge fund is a major shareholder of Palvella Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$233.55 (79.64% Upside)
$233.55 (79.64% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 52.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
272.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
232.03%
Trailing 12-Months
Company Description
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
PVLA Stock 12 Month Forecast
Average Price Target
$233.55
▲(79.64% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
―
Tyra Bioscience
―
Ownership Overview
1.92% Insiders
20.81% Mutual Funds
0.74% Other Institutional Investors
65.28% Public Companies and
Individual Investors